Half Year Results Analysts Presentation
Filed with ASX · · 32 pages · English
The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL. You can identify the
Earlier from CSL
- FY2017 Profit Upgrade
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- Positive Results from CSL112 Phase 2b Trial
- Afstyla CHMP Recommendation
- FDA Accepts BLA for Hereditary Angioedema Therapy
Later from CSL
- Half Year Results Release
- CSL to Acquire Majority Stake in Chinese Plasma Fractionator
- FDA approves CSL Berhings HAEGARDA
- CSL Response to Patent Infringement Complaint
- CSL Completes Acquisition of Majority Stake in Ruide
Follow CSL into a list and get an email when it puts out news.
Follow CSL